SSX-2 peptides presented by HLA class II molecules

Details SSX-2 peptides presented by HLA class II molecules SSX-2 peptides presented by HLA class II molecules

2011-08-02

2011-08-02

Gussow, Anne M. (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Peptides with at least one nonpeptide bond other than a...

C530S326000, C530S327000, C530S328000, C530S332000

Reexamination Certificate

active

07989587

ABSTRACT:
The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-2 gene.

REFERENCES:
patent: 5965535 (1999-10-01), Chaux et al.
patent: 6291658 (2001-09-01), Gure et al.
patent: 6339140 (2002-01-01), Gure et al.
patent: 6548064 (2003-04-01), Tureci et al.
patent: 6686147 (2004-02-01), Scanlan et al.
patent: 2005/0079553 (2005-04-01), Ayyoub et al.
patent: WO 00/20581 (2000-04-01), None
Li Zhu, Huang, and Xiong. Mutational analysis of the binding of staphylococcal enterotoxin D to the T cell receptor Vbeta chain and major histocompatibility complex class II. Immunology Letters, 2006. vol. 105, pp. 55-60.
Kersh, Miley, Nelson, Grakoui, Horvath, Donermeyer, Kappler, Allen, and Fremont. Structural and functional consequences of altering a peptide MHC anchor residue. Journal of Immunology, 2001. vol. 166, pp. 3345-3354.
Ayyoub, M. et al., SSX antigens as tumor vaccine targets in human sarcoma. Cancer Immunity 3: 13, 2003.
Ayyoub, M. et al., Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res 63: 5601-5606, 2003.
Ayyoub, M. et al., An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest 113(8): 1225-1233, 2004.
Ayyoub, M. et al., Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 168(4): 1717-1722, 2002.
Ayyoub, M. et al., Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. J Immunol 172(11): 7206-7211, 2004.
Chaux et al., Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189: 767-777, 1999.
Chen, Y.T. et al., A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94(5): 1914-1918, 1997.
Consogno, G. et al., Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 101(3): 1038-1044, 2003.
Crew et al., Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 14 (10) :2333-2340, 1995.
Dos Santos, N. R., et al., Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res., 60:1654-1662, 2000.
Gnjatic, S. et al., Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA 97(20): 10917-10922, 2000.
Gure, A.O. et al., SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer 72: 965-971, 1997.
Jäger, E. et al., Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187(2): 265-270, 1998.
James, R.F. et al., The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukemia cell line K36.16. Immunology 72(2): 213-218, 1991.
Kobayashi, H. et al., Defining promiscuous MHC class II helper T-cell epitopes for the HER2
eu tumor antigen. Cancer Res., 60:5228-5236, 2000.
Kubuschok, et al., Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model. Cancer Gene Ther 7(9): 1231-1240, 2000.
Mischo, et al., Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immun. 3: 5, 2003.
Mumberg, D. et al., CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96(15): 8633-8638, 1999.
Old, L.J. Cancer/testis (CT) antigens—a new link between gametogenesis and cancer. Cancer Immunity 1: 1, 2001.
Rammensee et al., SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 41:178-228, 1995.
Stockert, E. et al., A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187(8): 1349-1354, 1998.
Surman, S. et al., Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci USA 98(8): 4587-4592, 2001.
Thurner, B. et al., Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med., 190(11):1669-1678, (1999).
Toes, R.E. et al., CD4T cells and their role in antitumor immune responses. J Exp Med 189(5): 753-756, 1999.
Tureci, O. et al., The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 56(20): 4766-4772, 1996.
Tureci, O. et al., Expression of SSX genes in human tumors. Int J Cancer 77(1): 19-23, 1998.
Tureci, O. et al., Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci USA 95(9): 5211-5216, 1998.
Valmori, D. et al., Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med., 189(6):895-906, (1999).
Valmori et al., Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60: 4499-4506, 2000.
Valmori et al., Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res 61: 509-512, 2001.
Zaks, T.Z. et al., Immunization with a peptide epitope (p. 369-377) from HER-2
eu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2
eu+ tumors. Cancer Res 58(21): 4902-4908, 1998.
Zarour, H.M. et al., NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res 60(17): 4946-4952, 2000.
Zarour, H.M. et al., NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res 62(1): 213-218, 2002.
Zeng, G. et al., CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98(7): 3964-3969, 2001.
Zeng, G. et al., Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 165(2): 1153-1159, 2000.
Coulie, P.G., et al., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180: 35-42, 1994.
Hammer J., et al., Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning J Exp. Med. 180: 2353-2358, 1994.
Hung, K., et al., The Central Role of CD4+ T Cells in the Antitumor Immune Response. J. Exp. Med. 188(12): 2357-2368, 1998.
Kawakami, Y., et al., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352, 1994.
Robbins, P.F., et al., A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183: 1185-1192, 1996.
Jäger, E. et al., Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA. 97: 12198-12203, 2000.
Chen, C.H. et al., Expressions of cancer-testis antigens in hu

Affiliated with

Also associated with

Rating

SSX-2 peptides presented by HLA class II molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SSX-2 peptides presented by HLA class II molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SSX-2 peptides presented by HLA class II molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2716220